2018-03-08
org.kosen.entty.User@680cafc8
윤주용(juyongyoon)
Our focus is finding therapeutic solutions for patients with unmet medical needs. By developing cellular disease models directly from patient cells we develop therapeutic molecules up to the preclinical proof of concept, covering a “from bed to bench and back to bed” We view disease modeling ？as a competitive game changer in future drug development. iPSCs combined with the latest gene editing technologies can build highly relevant disease models that directly reflect human disease？ at a patient-specific level.？ The use of such models is likely ？to positively impact attrition during Phase II efficacy studies. Our strategy for competitiveness, therefore, expands well beyond libraries and Medchem. Combined with our high-end target free discovery platform and medicinal chemistry capacities, our approach is worldwide unique.
We view disease modeling as a competitive game changer in future drug development. iPSCs combined with the latest gene editing technologies can build highly relevant disease models that directly reflect human disease at a patient-specific level. The use of such models is likely to positively impact attrition during Phase II efficacy studies. Our strategy for competitiveness, therefore, expands well beyond libraries and Medchem. Combined with our high-end target free discovery platform and medicinal chemistry capacities, our approach is worldwide unique.
We view disease modeling as a competitive game changer in future drug development. iPSCs combined with the latest gene editing technologies can build highly relevant disease models that directly reflect human disease at a patient-specific level. The use of such models is likely to positively impact attrition during Phase II efficacy studies. Our strategy for competitiveness, therefore, expands well beyond libraries and Medchem. Combined with our high-end target free discovery platform and medicinal chemistry capacities, our approach is worldwide unique.
#Drug Discovery #DISEASE
국가
프랑스
소속기관
KSILINK (기업 및 산업체)
연락처
337-6997-8438 http://www.ksilink.com/
책임자
Ulf Nehrbass contact@ksilink.com
